JPS6115842A - インターフエロンと腫瘍壊死因子の相剰作用混合物 - Google Patents
インターフエロンと腫瘍壊死因子の相剰作用混合物Info
- Publication number
- JPS6115842A JPS6115842A JP60135823A JP13582385A JPS6115842A JP S6115842 A JPS6115842 A JP S6115842A JP 60135823 A JP60135823 A JP 60135823A JP 13582385 A JP13582385 A JP 13582385A JP S6115842 A JPS6115842 A JP S6115842A
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- necrosis factor
- tumor necrosis
- ifn
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 36
- 108010050904 Interferons Proteins 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 229940079322 interferon Drugs 0.000 title claims abstract description 30
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title claims abstract description 12
- 102000003390 tumor necrosis factor Human genes 0.000 title claims abstract description 12
- 230000002195 synergetic effect Effects 0.000 title abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 17
- 108010074328 Interferon-gamma Proteins 0.000 claims description 16
- 102000006992 Interferon-alpha Human genes 0.000 claims description 13
- 108010047761 Interferon-alpha Proteins 0.000 claims description 13
- 102000008070 Interferon-gamma Human genes 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 102000057041 human TNF Human genes 0.000 claims description 3
- 229960003130 interferon gamma Drugs 0.000 claims description 3
- 230000001613 neoplastic effect Effects 0.000 claims description 3
- 102000002227 Interferon Type I Human genes 0.000 claims 2
- 108010014726 Interferon Type I Proteins 0.000 claims 2
- 206010028851 Necrosis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 241001465754 Metazoa Species 0.000 abstract description 7
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 3
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 102100040247 Tumor necrosis factor Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 229940044627 gamma-interferon Drugs 0.000 description 6
- 229940047124 interferons Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000000824 cytostatic agent Substances 0.000 description 5
- 230000001085 cytostatic effect Effects 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 102100026720 Interferon beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241001330002 Bambuseae Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000710188 Encephalomyocarditis virus Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 244000292411 Excoecaria agallocha Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 208000010123 anthracosis Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- -1 lymphoxin Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19843423234 DE3423234A1 (de) | 1984-06-23 | 1984-06-23 | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| DE3423234.6 | 1984-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6115842A true JPS6115842A (ja) | 1986-01-23 |
Family
ID=6238998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60135823A Pending JPS6115842A (ja) | 1984-06-23 | 1985-06-21 | インターフエロンと腫瘍壊死因子の相剰作用混合物 |
Country Status (16)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62215535A (ja) * | 1986-01-24 | 1987-09-22 | ジエネンテク，インコ−ポレイテツド | ウイルス感染の予防および治療用組成物 |
| JPS62242629A (ja) * | 1986-04-09 | 1987-10-23 | シタス コ−ポレイシヨン | 腫瘍壊死因子を含んで成る組成物 |
| US11713216B2 (en) * | 2020-11-02 | 2023-08-01 | Otis Elevator Company | Safety exit assembly for elevator car, and elevator system |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| ATE73856T1 (de) * | 1984-12-21 | 1992-04-15 | Biogen Inc | Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. |
| US4828830A (en) * | 1986-01-24 | 1989-05-09 | Genentech, Inc. | Method and composition for prophylaxis and treatment of viral infections |
| US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
| CA1291706C (en) * | 1986-04-03 | 1991-11-05 | Alfred Rudolph | COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2 |
| US4863727A (en) * | 1986-04-09 | 1989-09-05 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| US5425940A (en) * | 1986-04-09 | 1995-06-20 | Cetus Oncology Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
| PT85076B (pt) * | 1986-06-16 | 1990-07-31 | Genentech Inc | Metodo para o tratamento de doencas infecciosas pela administracao de factor de necrose tumoral-alfa |
| US5362490A (en) * | 1986-07-25 | 1994-11-08 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Human myelomonocyte interferon-gamma, and process for preparation and use thereof |
| IL80005A (en) * | 1986-09-10 | 1992-11-15 | Yeda Res & Dev | Compositions for modulating the effect of tnf and il-1 |
| US4929442A (en) * | 1986-09-26 | 1990-05-29 | Exovir, Inc. | Compositions suitable for human topical application including a growth factor and/or related materials |
| US4980160A (en) * | 1986-10-16 | 1990-12-25 | Biogen, Inc. | Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases |
| US4963354A (en) * | 1987-01-21 | 1990-10-16 | Genentech, Inc. | Use of tumor necrosis factor (TNF) as an adjuvant |
| EP0392300B1 (de) * | 1989-04-11 | 1992-08-26 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Verwendung von mindestens ein Cytokin zur Herstellung eines Arzneimittels zur systemischen Behandlung von präneoplastischen Läsionen |
| US6042837A (en) * | 1989-09-20 | 2000-03-28 | Kalland; Terje | Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC) |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| AU674306B2 (en) * | 1992-02-10 | 1996-12-19 | Interferon Sciences Inc. | Improved alpha interferon composition and method for its production from human peripheral blood leukocytes |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| EP1416282A3 (en) * | 1995-07-25 | 2004-06-23 | Toray Industries, Inc. | Method for screening compounds for treating bone disorders |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US6599710B1 (en) | 1999-03-10 | 2003-07-29 | The General Hospital Corporation | Treatment of autoimmune disease |
| DK1238070T3 (da) * | 1999-12-13 | 2007-12-03 | Bioniche Life Sciences Inc | Terapeutisk anvendelige syntetiske oligonucleotider |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| IT1317835B1 (it) * | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
| US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| US7309694B2 (en) * | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
| CN1527721A (zh) * | 2000-09-12 | 2004-09-08 | 基因特罗生物治疗公司 | 含治疗性蛋白混合物的组合物及其生产方法 |
| US20030129162A1 (en) * | 2000-09-12 | 2003-07-10 | Lau Allan S. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| US20020150541A1 (en) * | 2000-09-12 | 2002-10-17 | Gene Trol Biotherapeutics, Inc. | Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| DE60316407T2 (de) * | 2002-02-06 | 2008-06-19 | Ares Trading S.A. | Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit |
| GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US7582313B2 (en) * | 2002-06-27 | 2009-09-01 | The General Hospital Corporation | Methods of organ regeneration using Hox 11-expressing pluripotent cells |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| WO2004045376A2 (en) * | 2002-11-15 | 2004-06-03 | The General Hospital Corporation | Screening methods to identify treatments for autoimmune disease |
| JP4754219B2 (ja) | 2002-12-02 | 2011-08-24 | アムジエン・フレモント・インコーポレイテツド | 腫瘍壊死因子を対象とする抗体、およびそれらの使用 |
| US20050148512A1 (en) * | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
| US20080102054A1 (en) * | 2005-01-18 | 2008-05-01 | Faustman Denise L | Compositions Containing Agm Cells And Methods Of Use Thereof |
| DE102012024749A1 (de) | 2012-12-11 | 2014-06-26 | Martin Röcken | Tumorprävention und -therapie durch Induktion einer Tumorseneszenz |
| HRP20211353T1 (hr) | 2013-02-07 | 2021-11-26 | The General Hospital Corporation | Postupci za ekspanziju ili depleciju regulacijskih t-stanica |
| US12174188B2 (en) | 2013-10-17 | 2024-12-24 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for type 1 diabetes and compositions for treating the same |
| ES2962885T3 (es) | 2015-05-15 | 2024-03-21 | Massachusetts Gen Hospital | Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| EP3355914B1 (en) | 2015-09-29 | 2024-03-06 | The General Hospital Corporation | A composition comprising bcg for reducing cholesterol. |
| KR102745778B1 (ko) | 2016-05-13 | 2024-12-24 | 더 제너럴 하스피탈 코포레이션 | 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체 |
| EP3743438A4 (en) * | 2018-01-24 | 2022-02-23 | Beijing Percans Oncology Co. Ltd. | CYTOKI FUSION PROTEINS |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5888322A (ja) * | 1981-11-21 | 1983-05-26 | Hayashibara Biochem Lab Inc | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2513124B1 (fr) * | 1981-07-21 | 1989-11-17 | Hayashibara Biochem Lab | Production et applications du facteur de lyse des cellules-cibles |
| IL71954A0 (en) * | 1983-06-01 | 1984-09-30 | Genentech Inc | Gamma interferon-lymphotoxin synergism |
| CA1265444A (en) * | 1983-06-27 | 1990-02-06 | Lloyd J. Old | Effect of human tumor necrosis factor and human interferon on human cancer cells and methods |
| DE3421731A1 (de) * | 1984-06-12 | 1985-12-12 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Humaner-tumor-nekrose-faktor |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
-
1984
- 1984-06-23 DE DE19843423234 patent/DE3423234A1/de not_active Ceased
-
1985
- 1985-06-19 GR GR851492A patent/GR851492B/el unknown
- 1985-06-20 EP EP85107618A patent/EP0170843B1/de not_active Expired - Lifetime
- 1985-06-20 PH PH32429A patent/PH24406A/en unknown
- 1985-06-20 US US06/746,793 patent/US4791101A/en not_active Expired - Fee Related
- 1985-06-20 DE DE8585107618T patent/DE3586833D1/de not_active Expired - Fee Related
- 1985-06-20 AT AT85107618T patent/ATE82508T1/de not_active IP Right Cessation
- 1985-06-21 CA CA000484739A patent/CA1258426A/en not_active Expired
- 1985-06-21 AU AU43931/85A patent/AU593212B2/en not_active Ceased
- 1985-06-21 IL IL75597A patent/IL75597A/xx not_active IP Right Cessation
- 1985-06-21 NZ NZ212513A patent/NZ212513A/xx unknown
- 1985-06-21 HU HU852456A patent/HU206270B/hu unknown
- 1985-06-21 IE IE154785A patent/IE59289B1/en not_active IP Right Cessation
- 1985-06-21 DK DK282585A patent/DK282585A/da not_active Application Discontinuation
- 1985-06-21 DD DD85295292A patent/DD250053A5/de not_active IP Right Cessation
- 1985-06-21 DD DD85277633A patent/DD238725A5/de not_active IP Right Cessation
- 1985-06-21 JP JP60135823A patent/JPS6115842A/ja active Pending
- 1985-06-21 ZA ZA854682A patent/ZA854682B/xx unknown
- 1985-06-24 AU AU44167/85A patent/AU4416785A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5888322A (ja) * | 1981-11-21 | 1983-05-26 | Hayashibara Biochem Lab Inc | 標的細胞障害性因子を含有する悪性腫瘍治療剤とその製造方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62215535A (ja) * | 1986-01-24 | 1987-09-22 | ジエネンテク，インコ−ポレイテツド | ウイルス感染の予防および治療用組成物 |
| JPS62242629A (ja) * | 1986-04-09 | 1987-10-23 | シタス コ−ポレイシヨン | 腫瘍壊死因子を含んで成る組成物 |
| US11713216B2 (en) * | 2020-11-02 | 2023-08-01 | Otis Elevator Company | Safety exit assembly for elevator car, and elevator system |
Also Published As
| Publication number | Publication date |
|---|---|
| GR851492B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-11-25 |
| DE3423234A1 (de) | 1986-02-06 |
| HUT37891A (en) | 1986-03-28 |
| DE3586833D1 (de) | 1992-12-24 |
| AU4416785A (en) | 1986-01-02 |
| IE851547L (en) | 1985-12-23 |
| EP0170843B1 (de) | 1992-11-19 |
| ZA854682B (en) | 1987-02-25 |
| IL75597A (en) | 1991-11-21 |
| ATE82508T1 (de) | 1992-12-15 |
| PH24406A (en) | 1990-06-13 |
| DD250053A5 (de) | 1987-09-30 |
| US4791101A (en) | 1988-12-13 |
| HU206270B (en) | 1992-10-28 |
| DK282585A (da) | 1985-12-24 |
| EP0170843A1 (de) | 1986-02-12 |
| IL75597A0 (en) | 1985-10-31 |
| IE59289B1 (en) | 1994-02-09 |
| NZ212513A (en) | 1988-08-30 |
| CA1258426A (en) | 1989-08-15 |
| DD238725A5 (de) | 1986-09-03 |
| AU593212B2 (en) | 1990-02-08 |
| AU4393185A (en) | 1986-01-02 |
| DK282585D0 (da) | 1985-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6115842A (ja) | インターフエロンと腫瘍壊死因子の相剰作用混合物 | |
| Le et al. | Biology of disease | |
| Kishimoto | The biology of interleukin-6 | |
| Schoenhaut et al. | Cloning and expression of murine IL-12 | |
| Fransen et al. | Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines | |
| Pestka et al. | Interleukin-10 and related cytokines and receptors | |
| Sayers et al. | Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation. | |
| Berent et al. | Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes | |
| Fiers et al. | Lymphokines and monokines in anti-cancer therapy | |
| Czarniecki | The role of tumor necrosis factor in viral disease | |
| Brack et al. | Hematopoietic growth factors: interactions and regulation of production | |
| Adolf | Structure and effects of interferon-gamma | |
| Hakoshima et al. | Crystallization and preliminary X-ray investigation reveals that tumor necrosis factor is a compact trimer furnished with 3-fold symmetry | |
| CZ2002195A3 (cs) | Farmaceutický prostředek pro inhibici produkce IL-18 | |
| Fiers et al. | Structure–Functton Relationship of Tumour Necrosis Factor and its Mechanism of Action | |
| JPS63264500A (ja) | 新規ポリペプチドおよびその製造法 | |
| Langer et al. | Purification, bacterial expression, and biological activities of the human interferons | |
| Hasegawa et al. | SFA-2, a novel bZIP transcription factor induced by human T-cell leukemia virus type I, is highly expressed in mature lymphocytes | |
| Oritani et al. | Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity | |
| Bollon et al. | Human cytokines, tumor necrosis factor, and interferons: gene cloning, animal studies, and clinical trials | |
| Rathjen et al. | Differential effects of small tumour necrosis factor-alpha peptides on tumour cell cytotoxicity, neutrophil activation and endothelial cell procoagulant activity | |
| Gase et al. | Critical role of the C-terminus in the biological activities of human tumour necrosis factor-alpha | |
| Ruggiero et al. | The in vitro antiviral activity of tumor necrosis factor (TNF) in WISH cells is mediated by IFN-β induction | |
| JP2564245B2 (ja) | ロイコレギュリン細胞表面レセプターに特異的なモノクローナル抗体、その製造法、及びその使用 | |
| Berman et al. | Tumor necrosis factor-α (TNF-α), interferon-α (IFN-α) and interferon-γ (IFN-γ) receptors on human normal and scleroderma dermal fibroblasts in vitro |